CoChat

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

Open access
Gong, Ying, Klein Wolterink, Roel G. J., Wang, Jianxiang, Bos, Gerard M. J., Germeraad, Wilfred T. V. · 2021 · Journal of Hematology & Oncology

The DOI matches its Crossref record; 234 of the 234 references it cites were found in a registry or an index.

Abstract

Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are considered as specialized immune cells that can be genetically modified to obtain capable effector cells for adoptive cellular treatment of cancer patients. However, biological and technical hurdles related to gene delivery into NK cells have dramatically restrained progress. Recent technological advancements, including improved cell expansion techniques, chimeric antigen receptors (CAR), CRISPR/Cas9 gene editing and enhanced viral transduction and electroporation, have endowed comprehensive generation and characterization of genetically modified NK cells. These promising developments assist scientists and physicians to design better applications of NK cells in clinical therapy. Notably, redirecting NK cells using CARs holds important promise for cancer immunotherapy. Various preclinical and a limited number of clinical studies using CAR-NK cells show promising results: efficient elimination of target cells without side effects, such as cytokine release syndrome and neurotoxicity which are seen in CAR-T therapies. In this review, we focus on the details of CAR-NK technology, including the design of efficient and safe CAR constructs and associated NK cell engineering techniques: the vehicles to deliver the CAR-containing transgene, detection methods for CARs, as well as NK cell sources and NK cell expansion. We summarize the current CAR-NK cell literature and include valuable lessons learned from the CAR-T cell field. This review also provides an outlook on how these approaches may transform current clinical products and protocols for cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-021-01083-5

Cites

234 of 234 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CAR-NK cells: growing interest and diversity of tumor targets. a Bar graph showing the number of manuscripts reporting experimental data on human CAR-NK cells until December 2020. Stacked bars show the number of publications per year with CAR-NK cells derived from cell lines (black) and primary NK cells (pink). b Tumor targets for cell line-derived (black) and primary NK cell-derived (pink) CAR-NK cells. Each symbol represents one study with experimental data, with blood drops for hematological malignancies and rectangles for solid malignancies. Numbers per tumor type are shown, with annotated boxes highlighting the most important tumor targets
Fig. 1 CAR-NK cells: growing interest and diversity of tumor targets. a Bar graph showing the number of manuscripts reporting experimental data on human CAR-NK cells until December 2020. Stacked bars show the number of publications per year with CAR-NK cells derived from cell lines (black) and primary NK cells (pink). b Tumor targets for cell line-derived (black) and primary NK cell-derived (pink) CAR-NK cells. Each symbol represents one study with experimental data, with blood drops for hematological malignancies and rectangles for solid malignancies. Numbers per tumor type are shown, with annotated boxes highlighting the most important tumor targetsCC BY · PubMed Central
Fig. 2 CAR-NK cell design. a Schematic overview of the building blocks for CAR-NK cells. From left to right: the extracellular single-chain variable fragment (scFv) consists linker-bound heavy and light chain and it determines the specificity of the CAR. The hinge region connects the tumor antigen-binding domain to the transmembrane region, ensures CAR stability and provides the flexibility for easy access to the target protein. The transmembrane region joins the extracellular and intracellular CAR domains, docks the CAR to the cell membrane and transduces activation signals to the intracellular activation signals. The number of intracellular activation domains determines the CAR generation. Various combinations of activating domains are used to mount a strong anti-tumor response. One example of a “fourth-generation” CAR is shown, co-expressing stimulating cytokines. Other examples of next-generation CAR constructs are discussed in Table 3. b and c Analysis of the most frequently used hinge (b) and transmembrane (c) regions for CAR-NK construction. Only studies reporting on the hinge region were included for this analysis. d Quantification of experimental studies with the indicated CAR-NK generations for cell line-derived (black) and primary NK cell-derived (pink) CAR-NK cells. e Pie charts showing the activation signals used for cell line-derived and primary cell CAR-NK cells, separated by CAR generation. Only the most frequently used combinations are shown
Fig. 2 CAR-NK cell design. a Schematic overview of the building blocks for CAR-NK cells. From left to right: the extracellular single-chain variable fragment (scFv) consists linker-bound heavy and light chain and it determines the specificity of the CAR. The hinge region connects the tumor antigen-binding domain to the transmembrane region, ensures CAR stability and provides the flexibility for easy access to the target protein. The transmembrane region joins the extracellular and intracellular CAR domains, docks the CAR to the cell membrane and transduces activation signals to the intracellular activation signals. The number of intracellular activation domains determines the CAR generation. Various combinations of activating domains are used to mount a strong anti-tumor response. One example of a “fourth-generation” CAR is shown, co-expressing stimulating cytokines. Other examples of next-generation CAR constructs are discussed in Table 3. b and c Analysis of the most frequently used hinge (b) and transmembrane (c) regions for CAR-NK construction. Only studies reporting on the hinge region were included for this analysis. d Quantification of experimental studies with the indicated CAR-NK generations for cell line-derived (black) and primary NK cell-derived (pink) CAR-NK cells. e Pie charts showing the activation signals used for cell line-derived and primary cell CAR-NK cells, separated by CAR generation. Only the most frequently used combinations are shownCC BY · PubMed Central
Fig. 3 Optimization strategies for CAR-NK cell generation. a Different vectors can be used to transduce NK cell lines and primary NK cells with CAR constructs. Quantification of the vectors used for CAR-NK generation. b Details of the various vectors used for CAR-NK generation. In blue, lentivirus generation, with third-generation viruses considered the safest option with minimal risk of in vivo recombination with other lentiviruses. In purple, the genus of retrovirus (alpha or gamma, or unknown). In green, the electroporated vector. c Various compounds have been identified that can be used to enhance virus-mediated transduction. For studies that employ virus-based strategies for CAR-NK generation, the methods used for enhancing virus transduction were quantified. d Primary cells for generation of CAR-NK cells are derived from different sources. Quantification of the four sources for primary NK cells for CAR-NK generation
Fig. 3 Optimization strategies for CAR-NK cell generation. a Different vectors can be used to transduce NK cell lines and primary NK cells with CAR constructs. Quantification of the vectors used for CAR-NK generation. b Details of the various vectors used for CAR-NK generation. In blue, lentivirus generation, with third-generation viruses considered the safest option with minimal risk of in vivo recombination with other lentiviruses. In purple, the genus of retrovirus (alpha or gamma, or unknown). In green, the electroporated vector. c Various compounds have been identified that can be used to enhance virus-mediated transduction. For studies that employ virus-based strategies for CAR-NK generation, the methods used for enhancing virus transduction were quantified. d Primary cells for generation of CAR-NK cells are derived from different sources. Quantification of the four sources for primary NK cells for CAR-NK generationCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 234 references

Research works printed but not linked: 1

  1. Gandara C, Affleck V, Stoll EA. Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to good manufacturing practice. Hum Gene Ther Methods. 2018;29(1):1–15. · DOI

Cited by

See all 379

Metadata

Authors
Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V.
Affiliations
  • Maastricht University Medical Centre (NL)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Germeraad, Wilfred T. V.
Venue
Journal of Hematology & Oncology
Published
2021-05-01
Volume
14
Issue
1
Pages
73-73
ISSN
1756-8722 (ISSN-L)
OpenAlex
W3157831753
Cited by
379
References
233
Citations by year
2026: 51 · 2025: 108 · 2024: 93 · 2023: 78 · 2022: 43 · 2021: 6
FWCI
6.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Funders
  • China Scholarship Council (201707720056)
  • Kootstra Talent Fellowship
  • Marie Skłodowska-Curie Individual fellowship (799810-TOPNIN)
  • Cancer Research Foundation Limburg (2012-03-KOFL)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CAR-NK cells, chimeric antigen receptor, natural killer cells, adoptive immunotherapy, cancer immunotherapy, gene delivery, viral transduction, electroporation, CRISPR/Cas9 genome editing, NK cell expansion, automotive design, cytokine release syndrome, neurotoxicity, car detection
MeSH terms
Receptors, Chimeric Antigen, Humans, Killer Cells, Natural, Neoplasms, Tissue Engineering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. https://app.cochat.ai/papers/10.1186/s13045-021-01083-5
The paper
Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021). Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-021-01083-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.